$2995 | Single User
$5990 | Site License
$8985 | Enterprise License

Human Immunodeficiency Virus (HIV) - Current and Future Players

Published by Global Data: 09 Sep 2015 | 27239 | In Stock

Introduction

Human Immunodeficiency Virus (HIV) - Current and Future Players

Summary

GlobalData has released its pharma report, “Human Immunodeficiency Virus (HIV) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Human Immunodeficiency Virus (HIV) Market. The report identifies and analyses the key companies shaping and driving the global Human Immunodeficiency Virus (HIV) market. The report provides insight into the competitive Human Immunodeficiency Virus (HIV) landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

- Investigation of current and future market competition for Human Immunodeficiency Virus (HIV)

- Competitor assessment

- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.

- Strategic assessment of Human Immunodeficiency Virus (HIV) sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Human Immunodeficiency Virus (HIV) market

- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

- Create an effective counter-strategy to gain a competitive advantage against those currently in the market

- What’s the next big thing in the global Human Immunodeficiency Virus (HIV) market landscape? Identify, understand and capitalize

Table of Contents
for Human Immunodeficiency Virus (HIV) - Current and Future Players

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 4

    1.2 List of Figures 5

    2 Introduction 6

    2.1 Catalyst 6

    2.2 Related Reports 7

    2.3 Upcoming Related Reports 7

    3 Market Outlook 8

    3.1 Global Markets 8

    3.1.1 Forecast 8

    3.1.2 Drivers and Barriers - Global Issues 14

    4 Current and Future Players 17

    4.1 Overview 17

    4.2 Trends in Corporate Strategy 19

    4.3 Company Profiles 21

    4.3.1 Gilead Sciences 21

    4.3.2 ViiV Healthcare 26

    4.3.3 AbbVie 31

    4.3.4 Merck & Co. 34

    4.3.5 Janssen 38

    4.3.6 Bristol-Myers Squibb 42

    4.3.7 Japan Tobacco 47

    4.3.8 Avexa 50

    4.3.9 TaiMed Biologics 53

    4.3.10 Tobira Therapeutics 55

    5 Appendix 59

    5.1 Bibliography 59

    5.2 Abbreviations 93

    5.3 Methodology 100

    5.4 Forecasting Methodology 100

    5.4.1 Total Prevalent Cases of HIV 100

    5.4.2 20-Year Diagnosed Prevalent Cases of HIV 100

    5.4.3 HIV Cases Treated with ART 101

    5.4.4 Drugs Included in Each Therapeutic Class 102

    5.4.5 Launch and Patent Expiry Dates 103

    5.4.6 General Pricing Assumptions 104

    5.4.7 Individual Drug Assumptions 106

    5.4.8 Generic Erosion 124

    5.4.9 Pricing of Pipeline Agents 124

    5.5 Primary Research - KOLs Interviewed for This Report 126

    5.6 Primary Research - Prescriber Survey 128

    5.7 About the Authors 129

    5.7.1 Analyst 129

    5.7.2 Epidemiologists 129

    5.7.3 Therapy Area Director 129

    5.7.4 Global Director of Therapy Analysis and Epidemiology 130

    5.7.5 Global Head of Healthcare 130

    5.8 About GlobalData 131

    5.9 Disclaimer 131

List Of Tables
in Human Immunodeficiency Virus (HIV) - Current and Future Players

1.1 List of Tables

Table 1: Global Sales Forecasts ($m) for HIV Therapeutics, 2013-2023 10

Table 2: Global HIV Therapeutics Market - Drivers and Barriers, 2013-2023 14

Table 3: Key Companies in the HIV-1 Market in the 9MM, 2014 18

Table 4: Gilead Sciences’ HIV Portfolio Assessment, 2014 25

Table 5: Gilead Sciences, SWOT Analysis in HIV, 2013-2023 26

Table 6: ViiV Healthcare’s HIV Portfolio Assessment, 2014 30

Table 7: ViiV Healthcare, SWOT Analysis in HIV, 2013-2023 31

Table 8: AbbVie’s HIV Portfolio Assessment, 2014 33

Table 9: AbbVie, SWOT Analysis in HIV, 2013-2023 34

Table 10: Merck & Co.’s HIV Portfolio Assessment, 2014 37

Table 11: Merck & Co., SWOT Analysis in HIV, 2013-2023 38

Table 12: Janssen’s HIV Portfolio Assessment, 2014 41

Table 13: Janssen, SWOT Analysis in HIV, 2013-2023 42

Table 14: BMS’ HIV Portfolio Assessment, 2014 46

Table 15: BMS, SWOT Analysis in HIV, 2013-2023 47

Table 16: Japan Tobacco’s HIV Portfolio Assessment, 2014 49

Table 17: Japan Tobacco, SWOT Analysis in HIV, 2013-2023 49

Table 18: Avexa’s HIV Portfolio Assessment, 2014 52

Table 19: Avexa, SWOT Analysis in HIV, 2013-2023 52

Table 20: TaiMed Biologics, HIV Portfolio Assessment, 2014 54

Table 21: TaiMed Biologics, SWOT Analysis in HIV, 2013-2023 55

Table 22: Tobira Therapeutics, HIV Portfolio Assessment, 2014 57

Table 23: Tobira Therapeutics, SWOT Analysis in HIV, 2013-2023 58

Table 24: Key Historical and Projected Launch Dates for HIV Therapeutics Across the 9MM 103

Table 25: Key Historical and Projected Patent Expiry Dates for HIV Therapeutics Across the 9MM 104

Table 26: High-Prescribing Physicians (non-KOLs) Surveyed, by Country 128

List Of Figures, Charts and Diagrams
in Human Immunodeficiency Virus (HIV) - Current and Future Players

1.2 List of Figures

Figure 1: Global Sales for HIV Therapeutics by Country, 2013-2023 12

Figure 2: Global Sales for HIV Therapeutics by Drug Class, 2013-2023 13

Figure 3: Company Portfolio Gap Analysis in HIV, 2013-2023 19

Additional Details

Publisher

Global Data

Publisher Information

Reference

27239 | GDHC1053FPR

Number of Pages

132

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Human Papilloma Virus Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs
Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover DrugsS...
01 May 2016 by CBR Pharma Insights USD $2,995 More Info
National Human Genome Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryNational Human Genome Research Institute (NHGRI) a subsidiary of National Institutes of Healt...
27 Apr 2016 by Global Data USD $250 More Info
National Human Genome Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryNational Human Genome Research Institute (NHGRI) a subsidiary of National Institutes of Healt...
14 Mar 2016 by Global Data USD $250 More Info
Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023SummaryHuman immuno...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023SummaryHuman imm...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - 5EU Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - 5EU Drug Forecast and Market Analysis to 2023SummaryHuman immun...
09 Sep 2015 by Global Data USD $6,995 More Info
Human Immunodeficiency Virus (HIV) - Brazil Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - Brazil Drug Forecast and Market Analysis to 2023SummaryHuman im...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - China Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - China Drug Forecast and Market Analysis to 2023SummaryHuman imm...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - Current and Future Players
Human Immunodeficiency Virus (HIV) - Current and Future PlayersSummaryGlobalData has released its ph...
09 Sep 2015 by Global Data USD $2,995 More Info

This report is published by Global Data

Download Free Report Summary PDF

Human Immunodeficiency Virus (HIV) - Current and Future Players | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data